Ozempic NAION warning infographic: FDA adds eye risk to all GLP-1 drug labels

The Ozempic NAION warning is now part of the label for every GLP-1 medicine sold in the United States. In a Drug Safety Communication dated 9 November 2026, the US Food and Drug Administration told makers of all 12 approved GLP-1 receptor agonists, from Ozempic and Wegovy to Mounjaro, Zepbound and the new oral Foundayo, to add non-arteritic anterior ischemic optic neuropathy (NAION), a rare cause of sudden vision loss, to the Warnings and Precautions section. The risk is small in absolute terms, but because millions of people take these drugs, including a fast-growing number in India, knowing the warning signs matters.

Key takeaways on Ozempic NAION warning

  • The warning applies class-wide: semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, lixisenatide and orforglipron products.
  • In an FDA pooled analysis of 126 trials, NAION occurred at 6.4 vs 3.8 cases per 100,000 person-years on GLP-1 drugs vs comparators.
  • In real-world US data, risk was higher than with DPP-4 inhibitors (hazard ratio 1.43) but not clearly higher than with SGLT-2 inhibitors.
  • Sudden, painless loss of vision in one eye, often noticed on waking, needs urgent medical attention.
  • Do not stop a prescribed GLP-1 drug on your own; discuss risks with your doctor, especially if you have had NAION before.

What is NAION?

NAION happens when blood flow to the front of the optic nerve drops, starving it of oxygen. The result is usually sudden, painless vision loss or a dark patch in part of the visual field of one eye. Some people notice dimmed colours or blurred central vision. There is no proven treatment to restore lost vision, and once one eye is affected the other eye carries a higher risk. In the general population, the FDA says, NAION affects roughly 2.3 to 10.2 people per 100,000 each year among adults over 50. Known risk factors include diabetes, high blood pressure, sleep apnoea, smoking, anaemia and kidney disease, which overlap heavily with the people who take GLP-1 drugs.

The evidence the FDA weighed

Concern began with a 2024 study in JAMA Ophthalmology from a Boston eye hospital that linked semaglutide to higher NAION rates. The FDA said that study had limitations, so it ran its own analyses before acting. The figures below are from the FDA Drug Safety Communication.

FDA analysisPopulationMain finding
Meta-analysis of 126 randomized trials134,253 patients; 288,879 person-years15 probable NAION events (10 on GLP-1, 5 on placebo); 6.4 vs 3.8 per 100,000 person-years
Sentinel cohort vs SGLT-2 inhibitorsUS adults with type 2 diabetes, 2019-2024HR 1.19 (95% CI 0.91-1.54), not statistically significant
Sentinel cohort vs DPP-4 inhibitorsSameHR 1.43 (95% CI 1.02-2.01), higher risk
Animal studiesNon-clinical dataNo biological mechanism identified

By our calculation, the trial data imply about 2.6 extra cases per 100,000 people treated for a year, or roughly one extra case for every 38,000 patient-years. That is rare. But GLP-1 use is now counted in the tens of millions worldwide, so even a rare effect means real patients. Europe reached a similar conclusion earlier: in mid-2025 the European Medicines Agency’s safety committee listed NAION as a very rare side effect of semaglutide, affecting up to 1 in 10,000 users.

Warning signs and what to do

The FDA’s advice to patients is practical. Seek help promptly if you notice any of these in one eye:

  • Sudden, painless loss of vision, often discovered on waking
  • A blurred or missing area in your field of view, often the upper or lower half
  • Colours that look faded or washed out
  • Reduced sharpness in the centre of your vision

Doctors are told to refer suspected cases to an ophthalmologist quickly and to consider stopping the GLP-1 drug if NAION is confirmed, unless the benefits clearly outweigh the risk. Anyone with a past episode of NAION should talk with their prescriber before starting or continuing treatment. Stopping on your own can raise blood sugar or undo weight loss, which carry their own risks.

What it means for patients in India

Semaglutide and tirzepatide use has grown quickly in India this year, helped by lower-cost semaglutide made by Indian drugmakers and by wider prescribing for diabetes and obesity. Diabetes and hypertension, two of the strongest NAION risk factors, are very common among Indian adults, so the warning is directly relevant here. At the time of writing we could not find an equivalent notice from India’s Central Drugs Standard Control Organisation (CDSCO), but the FDA advice applies to the molecule, not the brand, so it holds for generics too. People who buy these drugs from unregulated online sellers miss the medical supervision that would catch problems like this early.

The new warning adds to a growing picture of GLP-1 effects beyond weight. Recent research has pointed to possible benefits for the heart, covered in our GLP-1 heart failure study report, and open questions on the brain, discussed in Ozempic and dementia.

Market context

Safety labelling matters more as the market expands. Acumen Research and Consulting valued the global anti-obesity drugs market at $2.1 billion in 2022 and projected $8.2 billion by 2032, a 14.6% compound annual growth rate, with Asia-Pacific the fastest-growing region. The report was last updated in September 2023, before the biggest jump in GLP-1 demand, so treat it as a conservative baseline. Faster growth in Asia-Pacific, India included, means more first-time users who need clear information on rare side effects.

What is still unknown

The FDA has not shown that GLP-1 drugs cause NAION; it found a possible increased risk and no mechanism in animals. It is not known whether risk varies by dose, by drug or by how fast weight is lost, and whether people with sleep apnoea or poorly controlled diabetes face more of it. Larger long-term studies, and possibly regulators in other countries, will refine the picture. For more drug safety coverage, see our pharmaceutical news.

FAQ

Can Ozempic cause blindness?

Ozempic and other GLP-1 drugs may slightly raise the risk of NAION, which can cause permanent vision loss in one eye. The FDA calls it rare; trial data showed 6.4 cases per 100,000 person-years on GLP-1 drugs versus 3.8 on comparators.

Which drugs carry the new NAION warning?

All 12 US-approved GLP-1 receptor agonists, including Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Victoza, Saxenda, Xultophy, Soliqua, exenatide and Foundayo.

Should I stop taking semaglutide?

Not without speaking to your doctor. For most people the benefits outweigh this rare risk. Seek urgent care if you notice sudden vision loss in one eye.

Does the warning apply to generic semaglutide in India?

The FDA action covers US labels, but the possible risk relates to the medicine itself, so the same precautions sensibly apply to any semaglutide or tirzepatide product.

Sources: US FDA Drug Safety Communication (9 November 2026); European Medicines Agency PRAC (2025). Market data: Acumen Research and Consulting, Anti-Obesity Drugs Market report. This article is for information only and is not medical advice. Last updated 21 November 2026.

By Simone Lamb

Simone Lamb is the editor of Medgadget.in, covering healthcare technology, medical devices, and the latest developments in digital health.

Leave a Reply

Your email address will not be published. Required fields are marked *